Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results

Abstract:
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on Wednesday, May 3, 2017, at 4:30 p.m. EDT to discuss its financial results for the fiscal 2017 second quarter ended March 31, 2017.

Arrowhead Pharmaceuticals to Webcast Fiscal 2017 Second Quarter Results

Pasadena. CA | Posted on April 27th, 2017

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and enter Conference ID 12326590.

A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 855-859-2056 or 404-537-3406 and enter Conference ID 12326590.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Matthew P. Duffy, 212-915-0685

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Epoxy compound gets a graphene bump: Rice scientists combine graphene foam, epoxy into tough, conductive composite November 14th, 2018

Optimization of alloy materials: Diffusion processes in nano particles decoded November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

Nanomedicine

Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018 November 9th, 2018

Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018 November 9th, 2018

WSU researchers develop new technique to understand biology at the nanoscale November 7th, 2018

A record-long polymer DNA negative November 6th, 2018

Announcements

Epoxy compound gets a graphene bump: Rice scientists combine graphene foam, epoxy into tough, conductive composite November 14th, 2018

Optimization of alloy materials: Diffusion processes in nano particles decoded November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

GLOBALFOUNDRIES, indie Semiconductor Deliver Performance-Enhanced Microcontrollers for Automotive Applications: 55nm LPx platform, with SST’s highly reliable embedded SuperFlash®, increases performance and energy efficiency for automotive applications November 13th, 2018

Financial Reports

180 Degree Capital Corp. Reports Net Asset Value Per Share of $2.81 as of September 30, 2018; a Decrease of 3.4% From June 30, 2018 October 29th, 2018

180 Degree Capital Corp. to Report Third Quarter 2018 Financial Results on Monday, October 29, 2018 and to Host a Conference Call on Tuesday, October 30, 2018 October 24th, 2018

Nanometrics to Announce Third Quarter Financial Results on October 30, 2018 October 10th, 2018

Nanometrics to Announce Second Quarter Financial Results on July 31, 2018 July 12th, 2018

Events/Classes

Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018 November 9th, 2018

Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018 November 9th, 2018

IEDM - CEA-Leti Will Present 11 Papers and Host Workshop on Disruptive Technologies for Data Management November 7th, 2018

AIM Photonics Members Meeting Provides Key Updates on the Initiative’s Progress: Day-Long Engagement in Syracuse, NY, Sees Strong Attendance and Interest from Industry, Government, and Academic Partners November 2nd, 2018

Nanobiotechnology

Arrowhead Pharmaceuticals Presents Late-Breaking Clinical Data on ARO-AAT at Liver Meeting® 2018 November 9th, 2018

Arrowhead Pharmaceuticals Presents Late-Breaking Preliminary Clinical Data on ARO-HBV at Liver Meeting® 2018 November 9th, 2018

WSU researchers develop new technique to understand biology at the nanoscale November 7th, 2018

A record-long polymer DNA negative November 6th, 2018

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project